Our long-standing partnership with Gavi, the Vaccine Alliance, spans over two decades. During that time, we’ve supplied more than 1bn doses of vaccines, helping to prevent childhood diseases and supporting the expansion of immunisation programmes in lower income countries. It’s crucial that children have access to vital childhood immunisations, which is why Gavi has set ambitious new goals to improve vaccine access and strengthen health systems from 2026 to 2030. We’re committed to supporting Gavi’s strategy through our global health partnerships across lower income countries. In this blog post, our Global Health Policy Lead, Ariane McCabe and Save the Children UK’s Interim Executive Director of Policy, Advocacy and Campaigns, @Dan Paskins, share why we’re both pledging our continued support for Gavi and its mission, and how our work together on reaching zero dose children is helping move us closer to a world where every child, regardless of where they are born, has the chance to survive and thrive: https://gsk.to/3zXBMS6 #WHS2024 #ChangeTheTrajectory #HealthForAll
GSK
Fabricación de productos farmacéuticos
Brentford, Middlesex 4.105.305 seguidores
Sobre nosotros
We are uniting science, technology and talent to get ahead of disease together. Our community guidelines: https://gsk.to/socialmedia
- Sitio web
-
http://www.gsk.com
Enlace externo para GSK
- Sector
- Fabricación de productos farmacéuticos
- Tamaño de la empresa
- Más de 10.001 empleados
- Sede
- Brentford, Middlesex
- Tipo
- Empresa pública
- Especialidades
- Pharmaceutical products y Vaccines
Ubicaciones
Empleados en GSK
Actualizaciones
-
We’re delighted to have partnered with Save the Children UK for over 10 years, in our shared mission to help improve the health of children across more than 20 countries. Together, we’ve focussed on important programmes, such as childhood immunisation, strengthening community healthcare systems and improving maternal and newborn health. At yesterday’s “10 Years of Global Health Excellence 2024 Symposium”, sponsored by GSK, Save the Children gathered key people who’ve seen firsthand the impact of our collaborative efforts over the years. They reflected on the critical success factors and barriers to sustained change in health policy and health systems and shared insights from some of our flagship programmes including INSPIRING, which aimed to help reduce childhood deaths from pneumonia and other preventable infectious diseases in Nigeria and our work in helping reduce death and disease among pregnant women and newborns in Kenya. Thanks to everyone who took part! Our partnership continues until every child is protected from vaccine-preventable diseases and enjoys good health. Find out more: https://lnkd.in/g3rfXng5 #ChangeTheTrajectory
-
News for #Media and #Investors: Today we announced, in collaboration with ViiV Healthcare, our specialist HIV company, the presentation of 60 abstracts to showcase advances across our industry-leading infectious disease pipeline and portfolio at #IDWeek2024. 🔗 Learn more: https://gsk.to/3Y0Y3Gz
-
We’re excited to be attending #CHEST2024 where we’re engaging with thought leaders and experts in pulmonary health. With approximately 177,000 US adults 65 years and older hospitalised due to RSV infection each year, it is important that we unite our efforts to get ahead of this virus, together.
-
#News for #Investors and #Media: Today we shared data at #CHEST2024 on one of our vaccines. Learn more: https://gsk.to/3Nfcq50
-
Around 1 in 5 invasive meningococcal disease (IMD) survivors are left with severe long-term after-effects, such as permanent physical disabilities. Survivors like Rodolpho. Now an amputee, paralympic equestrian champion Rodolpho shares his powerful story to warn others of the dangers of IMD. As we close #WorldMeningitisDay for another year, his testimony serves as our inspiration as we harness science and technology to work towards a meningococcal-free world by 2030. Find out more about Rodolpho’s story here: https://gsk.me/3TYJySl #DefeatMeningitis
-
News for #Media and #Investors from our specialist HIV company, ViiV Healthcare, on their commitment to increasing access to #HIV PrEP in low- and middle-income countries and Sub-Saharan Africa. Find out more: https://www.gsk.com/en-gb/
-
Invasive meningococcal disease (IMD) is a devastating disease caused by the bacteria Neisseria meningitidis, and affects around 1.2 million people around the world, each year. Among those who contract IMD, 1 in 6 will die, sometimes in as little as 24 hours. At GSK, we are committed to working towards a meningococcal-free world by finding solutions through our science and technology. As we close #WorldMeningitisDay for another year, take a moment to learn more about this disease 👇 #DefeatMeningitis
-
We’re incredibly proud that our CEO Emma Walmsley, has been named to Fortune Magazine's list of the 100 most powerful women, alongside other accomplished leaders in the Fortune 500 and Global 500.